November 15, 2018
The new and improved iCELLis 500+ bioreactor system will simplify large scale cGMP production of virus for vaccines or gene therapy. New features provide enhanced robust control, reliability, and sustainability of high-density adherent cell growth in an automated format.
Boasting a new stainless steel frame and temperature control unit (TCU), the iCELLis 500+ bioreactor is fully compatible with 21 CFR Part 11 standards and cleanroom requirements.
It features an integrated recipe manager, improved tubing management, and a new temperature control unit (TCU), enabling greater process control, faster filling and draining, and further automations of customer processes for cell and gene therapy and vaccines.